Methotrexate Accord (Methotrexate)

Methotrexate functions as a folate antagonist. By inhibiting the enzyme dihydrofolate reductase, it blocks the formation of tetrahydrofolate, a key cofactor for synthesising purines and pyrimidines. This interruption limits DNA, RNA and protein production, which particularly affects rapidly dividing cells and immune cells.

The dose of Methotrexate Accord is individualized by the prescribing clinician. Factors such as the specific disease being treated, patient weight, renal and hepatic function, and concurrent medications are evaluated to select an appropriate dosing regimen. Patients should follow the prescriber’s instructions precisely.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended for breastfeeding mothers, as it can be excreted in milk and may harm the infant.

To request Methotrexate Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Methotrexate is one of the most widely used antimetabolites and is often compared with agents such as azathioprine or mycophenolate. Compared with newer biologics, methotrexate is less expensive but may require more laboratory monitoring. Its efficacy in rheumatoid arthritis and certain cancers remains well‑established, though individual response varies.

Methotrexate Accord should be stored at controlled room temperature, typically below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use. Follow any additional handling instructions provided with the shipment.

Methotrexate Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intrathecal routes, depending on the clinical indication and prescriber’s plan. Administration is performed by qualified healthcare professionals in a controlled setting, with dosing intervals determined by the treating physician.

The most serious risks of methotrexate include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Prompt monitoring and early detection are essential to mitigate these hazards.

Methotrexate Accord should be avoided in pregnant or nursing women, patients with severe renal or hepatic impairment, those with existing bone‑marrow disorders, and individuals receiving live vaccines. It is also contraindicated in patients with known hypersensitivity to methotrexate or any of its excipients.